Justin Stebbing: The first time invariant natural killer cells has ever been used as a cell therapy

Justin Stebbing shared a post on LinkedIn:

“Super-thrilled to see our paper finally out in Nature Communications, the first time invariant natural killer cells, a type of T cell, has ever been used as a cell therapy. We were able to rapidly scale this during the pandemic and all our patients were ventilated and critically unwell with acute respiratory distress syndrome (5 on vv-ECMO). It looks really safe, and there are tantalising signs of efficacy including persistence of this unique cell type, which bridges the innate and adaptive immune systems, in the patients. So many thanks to an amazing team to get this out there, especially to the Team at Mink run by Jennifer Buell, Mark Exley, Marco Purbhoo and Marc van Dijk and the investigators led by Terese Hammond. ”

Read further.
Source: Justin Stebbing/LinkedIn

Justin Stebbing is a visiting Professor of Cancer Medicine and Oncology at Imperial College, London and a Professor of Biomedical Sciences at Anglia Ruskin University (ARU), Cambridge. He was appointed the first NIHR oncology professor in 2011. He is editor-in-chief of Nature’s cancer journal Oncogene. Prof. Stebbing has published over 700 peer-reviewed papers in leading academic journals. He is a member of the American Society for Clinical Investigation, a fellow of the Royal College of Physicians, and the Royal College of Pathologists, and sits on many advisory boards. He is on the Editorial Board of OncoDaily.